PMID- 27275819
OWN - NLM
STAT- MEDLINE
DCOM- 20170406
LR  - 20181113
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 17
IP  - 6
DP  - 2016 Jun 6
TI  - Could Vitamin D Analogues Be Used to Target Leukemia Stem Cells?
LID - 10.3390/ijms17060889 [doi]
LID - 889
AB  - Leukemic stem cells (LSCs) are defined as cells that possess the ability to 
      self-renew and give rise to the differentiated cancer cells that comprise the 
      tumor. These LSCs seem to show chemo-resistance and radio-resistance leading to 
      the failure of conventional cancer therapies. Current therapies are directed at 
      the fast growing tumor mass leaving the LSC fraction untouched. Eliminating LSCs, 
      the root of cancer origin and recurrence, is considered to be a hopeful approach 
      to improve survival or even to cure cancer patients. In order to achieve this, 
      the characterization of LSCs is a prerequisite in order to develop LSC-based 
      therapies to eliminate them. Here we review if vitamin D analogues may allow an 
      avenue to target the LSCs.
FAU - Garcia-Ramirez, Idoia
AU  - Garcia-Ramirez I
AD  - Experimental Therapeutics and Translational Oncology Program, Instituto de 
      Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, 
      Campus M. de Unamuno s/n, Salamanca 37007, Spain. idoia.g@usal.es.
AD  - Cancer Research Area, Institute of Biomedical Research of Salamanca (IBSAL), 
      Salamanca 37007, Spain. idoia.g@usal.es.
FAU - Martin-Lorenzo, Alberto
AU  - Martin-Lorenzo A
AD  - Experimental Therapeutics and Translational Oncology Program, Instituto de 
      Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, 
      Campus M. de Unamuno s/n, Salamanca 37007, Spain. trioney@usal.es.
AD  - Cancer Research Area, Institute of Biomedical Research of Salamanca (IBSAL), 
      Salamanca 37007, Spain. trioney@usal.es.
FAU - Gonzalez-Herrero, Ines
AU  - Gonzalez-Herrero I
AD  - Experimental Therapeutics and Translational Oncology Program, Instituto de 
      Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, 
      Campus M. de Unamuno s/n, Salamanca 37007, Spain. ighe@usal.es.
AD  - Cancer Research Area, Institute of Biomedical Research of Salamanca (IBSAL), 
      Salamanca 37007, Spain. ighe@usal.es.
FAU - Rodriguez-Hernandez, Guillermo
AU  - Rodriguez-Hernandez G
AD  - Experimental Therapeutics and Translational Oncology Program, Instituto de 
      Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, 
      Campus M. de Unamuno s/n, Salamanca 37007, Spain. guillermorh@usal.es.
AD  - Cancer Research Area, Institute of Biomedical Research of Salamanca (IBSAL), 
      Salamanca 37007, Spain. guillermorh@usal.es.
FAU - Vicente-Duenas, Carolina
AU  - Vicente-Duenas C
AD  - Cancer Research Area, Institute of Biomedical Research of Salamanca (IBSAL), 
      Salamanca 37007, Spain. cvd@usal.es.
FAU - Sanchez-Garcia, Isidro
AU  - Sanchez-Garcia I
AD  - Experimental Therapeutics and Translational Oncology Program, Instituto de 
      Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, 
      Campus M. de Unamuno s/n, Salamanca 37007, Spain. isg@usal.es.
AD  - Cancer Research Area, Institute of Biomedical Research of Salamanca (IBSAL), 
      Salamanca 37007, Spain. isg@usal.es.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160606
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Receptors, Calcitriol)
RN  - 1406-16-2 (Vitamin D)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Epigenesis, Genetic/drug effects
MH  - Hematopoietic Stem Cells/drug effects/metabolism
MH  - Humans
MH  - Leukemia/*drug therapy/genetics/*metabolism
MH  - Molecular Targeted Therapy
MH  - Neoplastic Stem Cells/*drug effects/*metabolism
MH  - Receptors, Calcitriol/metabolism
MH  - Vitamin D/analogs & derivatives/*pharmacology/*therapeutic use
PMC - PMC4926423
OTO - NOTNLM
OT  - cancer
OT  - cancer stem cells
OT  - leukemia therapy
OT  - mouse models
OT  - stem cells
OT  - vitamin D
EDAT- 2016/06/09 06:00
MHDA- 2017/04/07 06:00
PMCR- 2016/06/01
CRDT- 2016/06/09 06:00
PHST- 2016/04/25 00:00 [received]
PHST- 2016/05/23 00:00 [revised]
PHST- 2016/05/31 00:00 [accepted]
PHST- 2016/06/09 06:00 [entrez]
PHST- 2016/06/09 06:00 [pubmed]
PHST- 2017/04/07 06:00 [medline]
PHST- 2016/06/01 00:00 [pmc-release]
AID - ijms17060889 [pii]
AID - ijms-17-00889 [pii]
AID - 10.3390/ijms17060889 [doi]
PST - epublish
SO  - Int J Mol Sci. 2016 Jun 6;17(6):889. doi: 10.3390/ijms17060889.